The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy

Landon C. Brown, Meghan A. Jobson, Fernanda Payan Schober, Emily H. Chang, Ronald J. Falk, Patrick H. Nachman, William F. Pendergraft

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: Minimal-change glomerulopathy is defined histologically by the presence of normal glomeruli on light microscopy and diffuse podocyte effacement on electron microscopy. Although effective in children, corticosteroid treatment in adults is more variable and time to response can be prolonged. Data to support rituximab use in adults with corticosteroid-dependent or resistant minimal-change glomerulopathy are limited. Here, we describe the clinical course of adults with corticosteroid-dependent or-resistant minimal-change glomerulopathy who received rituximab. Methods: Demographic and clinical data were collected and analyzed from all adult patients with native kidney, biopsy-proven, minimal-change glomerulopathy who were administered rituximab between 2009 and 2014 and cared for at the UNC Kidney Center. Results: Ten patients with corticosteroid-resistant (n = 5) or corticosteroid-dependent (n = 5) idiopathic minimal-change glomerulopathy were treated with rituximab between 2009 and 2014. Rituximab treatment induced remission in all 10 patients with a median time to remission of 2 months. The median time from rituximab to corticosteroid discontinuation was 3.5 months. The median remission time was 29 months and follow-up time was 39.5 months. No serious adverse events attributable to rituximab were observed. Conclusion: Rituximab induced remission in all patients with corticosteroid-dependent or-resistant minimal-change glomerulopathy, and may hold great therapeutic potential with good efficacy and minimal toxicity. Mounting evidence implies that a well-conducted randomized controlled clinical trial using rituximab in adults with minimal-change glomerulopathy in both corticosteroid-resistant and corticosteroid-dependent patients is warranted.

Original languageEnglish (US)
Pages (from-to)365-372
Number of pages8
JournalAmerican Journal of Nephrology
Issue number4
StatePublished - Apr 1 2017
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017 S. Karger AG, Basel.


  • Minimal change glomerulopathy
  • Outcomes
  • Rituximab


Dive into the research topics of 'The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy'. Together they form a unique fingerprint.

Cite this